27645456|t|Maternal Immunization with Pneumococcal Polysaccharide Vaccine: Persistence of Maternal Antibodies in Infants
27645456|a|To evaluate the level and the persistence of maternal antibodies in infants after maternal immunization with pneumococcal polysaccharide vaccine (Pn23V). Pregnant women were assigned to two groups, during routine low-risk pre-natal visits. The first Group (VAC) received the Pn23V vaccine shortly after enrolment at 28 weeks or later, and the second Group (NO _ VAC) received no vaccine. To investigate the antibody persistence, we collected blood samples from the mothers after 1 month of delivery and from the infants at 1 and 6 months of age. Antibody titers were measured for serotypes 1, 6B and 14. Geometric mean antibody concentrations of specific immunoglobulin G were significantly higher in the vaccinated group compared with unvaccinated controls for all three serotypes tested. Despite the antibody level's decline, at 6 months of age, proportions >0.35 Î¼g/ml remained higher in the infants of vaccinated mothers than controls for all three serotypes.
27645456	0	8	Maternal	T033	C1858460
27645456	9	21	Immunization	T061	C0020971
27645456	27	62	Pneumococcal Polysaccharide Vaccine	T121,T129	C0305065
27645456	79	87	Maternal	T033	C1858460
27645456	88	98	Antibodies	T116,T129	C0003241
27645456	102	109	Infants	T100	C0021270
27645456	155	163	maternal	T033	C1858460
27645456	164	174	antibodies	T116,T129	C0003241
27645456	178	185	infants	T100	C0021270
27645456	192	200	maternal	T033	C1858460
27645456	201	213	immunization	T061	C0020971
27645456	219	254	pneumococcal polysaccharide vaccine	T121,T129	C0305065
27645456	256	261	Pn23V	T121,T129	C0305065
27645456	264	278	Pregnant women	T098	C0033011
27645456	300	306	groups	T098	C1257890
27645456	332	348	pre-natal visits	T058	C1827763
27645456	354	359	first	T081	C0205435
27645456	360	365	Group	T098	C1257890
27645456	367	370	VAC	T121,T129	C0042210
27645456	385	390	Pn23V	T121,T129	C0305065
27645456	391	398	vaccine	T121,T129	C0042210
27645456	429	434	weeks	T079	C0439230
27645456	453	459	second	T081	C0205436
27645456	460	465	Group	T098	C1257890
27645456	467	469	NO	T033	C1513916
27645456	472	475	VAC	T121,T129	C0042210
27645456	486	488	no	T033	C1513916
27645456	489	496	vaccine	T121,T129	C0042210
27645456	517	525	antibody	T116,T129	C0003241
27645456	552	565	blood samples	T031	C0178913
27645456	575	582	mothers	T099	C0026591
27645456	591	596	month	T079	C0439231
27645456	622	629	infants	T100	C0021270
27645456	641	647	months	T079	C0439231
27645456	651	654	age	T032	C0001779
27645456	656	664	Antibody	T116,T129	C0003241
27645456	690	701	serotypes 1	T170	C0580279
27645456	703	705	6B	T170	C0449943
27645456	710	712	14	T170	C0449943
27645456	714	728	Geometric mean	T081	C2986759
27645456	729	737	antibody	T116,T129	C0003241
27645456	765	781	immunoglobulin G	T116,T121,T129	C0020852
27645456	815	825	vaccinated	T033	C1519885
27645456	826	831	group	T098	C1257890
27645456	846	858	unvaccinated	T033	C1513916
27645456	882	891	serotypes	T170	C0449943
27645456	912	920	antibody	T116,T129	C0003241
27645456	943	949	months	T079	C0439231
27645456	953	956	age	T032	C0001779
27645456	1005	1012	infants	T100	C0021270
27645456	1016	1026	vaccinated	T033	C1519885
27645456	1027	1034	mothers	T099	C0026591
27645456	1063	1072	serotypes	T170	C0449943